

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 April 2022 (14.04.2022)



(10) International Publication Number
WO 2022/076328 A1

(51) International Patent Classification:

A61K 9/16 (2006.01) *A61K 9/00* (2006.01)
A61K 9/20 (2006.01) *A61K 31/00* (2006.01)
A61K 9/50 (2006.01) *A61K 9/46* (2006.01)

(21) International Application Number:

PCT/US2021/053416

(22) International Filing Date:

04 October 2021 (04.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2020/119816

05 October 2020 (05.10.2020) CN


(71) Applicant: **THERACOS SUB, LLC** [US/US]; 225 Cedar Hill Street, Suite 200, Marlborough, Massachusetts 01752 (US).

(72) Inventors: **WANG, Feng**; c/o Theracos Sub, LLC, 225 Cedar Hill Street, Suite 200, Marlborough, Massachusetts

01752 (US). **SHRIVASTAVA, Ankit**; c/o Theracos Sub, LLC, 225 Cedar Hill Street, Suite 200, Marlborough, Massachusetts 01752 (US). **SHAH, Rina**; c/o Theracos Sub, LLC, 225 Cedar Hill Street, Suite 200, Marlborough, Massachusetts 017452 (US). **SEED, Brian**; c/o Theracos Sub, LLC, 225 Cedar Hill Street, Suite 200, Marlborough, Massachusetts 01752 (US). **PATIL, Vinay**; c/o Theracos Sub, LLC, 225 Cedar Hill Street, Suite 200, Marlborough, Massachusetts 01752 (US). **HADD, Michael J.**; c/o Theracos Sub, LLC, 225 Cedar Hill Street, Suite 200, Marlborough, Massachusetts 01752 (US). **DONG, Fuxia**; c/o Theracos Sub, LLC, 225 Cedar Hill Street, Suite 200, Marlborough, Massachusetts 01752 (US). **DHALL, Vipin**; c/o Theracos Sub, LLC, 225 Cedar Hill Street, Suite 200, Marlborough, Massachusetts 01752 (US). **DAI, Chunfeng**; c/o Theracos Sub, LLC, 225 Cedar Hill Street, Suite 200, Marlborough, Massachusetts 01752 (US). **CHAU, Joseph Ho-Lun**; c/o Theracos Sub, LLC, 225 Cedar Hill Street, Suite 200, Marlborough, Massachusetts 01752 (US). **CAI, Qiuhua**; c/o Theracos Sub, LLC, 225 Cedar Hill Street, Suite 200, Marlborough, Massachusetts 01752 (US).

(54) Title: PHARMACEUTICAL FORMULATIONS

FIGURE 2



(57) Abstract: The pharmacokinetic profile of the SGLT2 inhibitor bexagliflozin can be improved by formulating it as an extended release tablet. Compared with standard immediate-release dosage forms these tablets can permit a lower peak plasma concentration, C_{max} , while maintaining plasma concentrations at therapeutic levels for a desired period. This can be used, for instance, to administer lower doses while still providing the same pharmacological effect.

[Continued on next page]

(74) **Agent: KEZER, William B.** et al.; Mintz Levin Cohn, Ferris Glovsky & Popeo, P.C., One Financial Center, Boston, Massachusetts 02111 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))